Document is current
Any future updates will be listed below
-
Authors
Rice, Siobhan
Jackson, Thomas
Crump, Nicholas T. http://orcid.org/0000-0001-9610-6763
Fordham, Nicholas
Elliott, Natalina
O’Byrne, Sorcha
Fanego, Maria del Mar Lara
Addy, Dilys
Crabb, Trisevgeni
Dryden, Carryl
Inglott, Sarah
Ladon, Dariusz
Wright, Gary
Bartram, Jack
Ancliff, Philip
Mead, Adam J. http://orcid.org/0000-0001-8522-1002
Halsey, Christina http://orcid.org/0000-0001-5449-5246
Roberts, Irene
Milne, Thomas A. http://orcid.org/0000-0002-0413-4271
Roy, Anindita http://orcid.org/0000-0001-8607-5748
-
Funding
Funding for this research was provided by:
Wellcome Trust (216632/Z/19/Z)
Lady Tata Memorial Trust
Bloodwise (17001)
- License Information
-
More Information
Article History
Received: 19 November 2020
Accepted: 8 November 2021
First Online: 25 November 2021
Competing interests
: T.A.M. is a founding shareholder of OxStem Oncology (OSO), a subsidiary company of OxStem Ltd. T.A.M. and N.T.C. are founding shareholders and paid consultants for Sandymount Therapeutics (a subsidiary company of Dark Blue Therapeutics). S.O’B. is now an employee of Becton, Dickinson and Company (BD). S.O’B.’s contributions to the work were made prior to the commencement of employment at BD. The other authors declare no competing interests.
